48
Participants
Start Date
April 3, 2021
Primary Completion Date
October 8, 2023
Study Completion Date
December 8, 2023
Nimotuzumab+CRT(concurrent IMRT and TMZ)
"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
RECRUITING
The Third People's Hospital of Zhengzhou, Zhengzhou
NOT_YET_RECRUITING
Xiangya Hospital of Centre-south University, Changsha
NOT_YET_RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Beijing Tiantan Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Xuanwu Hospital Capital Medical University, Beijing
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
OTHER